세계의 폐렴 치료제 시장 보고서(2025년)

Pneumonia Therapeutics Global Market Report 2025

US $ 4,490 ￦ 6,242,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,023,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 11,803,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

폐렴 치료제 시장 규모는 향후 몇 년 동안 빠르게 성장할 것으로 예상됩니다. 2029년에는 10.7%의 연평균 성장률(CAGR)로 172억 6,000만 달러까지 성장할 것으로 예상됩니다. 예측 기간의 성장은 항생제 내성 균주의 유병률 증가, 고령화 인구의 폐렴 발병률 증가, 조기 진단을 위한 원격 의료의 확대, 신흥 시장의 의료비 지출 증가, 감염병 연구 자금 증가, 인식 캠페인 강화 등에 기인한 것으로 볼 수 있습니다. 이 기간 동안 예상되는 주요 트렌드로는 단일 클론 항체 개발, 흡입용 항생제 도입, mRNA 기반 백신의 혁신, AI 기반 진단 도구, 숙주 표적 치료법, 새로운 면역 조절제, 신속한 현장 진단 플랫폼의 발전 등이 있습니다.

폐렴의 유병률 증가는 폐렴 치료제 시장의 성장을 견인할 것으로 예상됩니다. 폐렴은 공기주머니에 염증을 일으켜 기침, 발열, 호흡곤란 등의 증상을 유발하는 폐 감염입니다. 폐렴의 발병률 증가는 인구 고령화, 대기 오염, 흡연, 면역 체계 약화, 항균제 내성, 코로나19 및 인플루엔자와 같은 호흡기 감염의 확산 등의 요인에 기인합니다. 폐렴 치료제는 표적 약물을 통해 박테리아, 바이러스, 곰팡이 등 감염의 근본 원인에 대처하는 동시에 산소 치료, 항염증제, 증상 관리로 회복을 지원하도록 설계되었습니다. 예를 들어, 2023년 1월 미국 국립생명공학정보센터는 매년 전 세계적으로 약 1억 2,000만 명이 폐렴에 걸리고 약 130만 명이 사망한다고 보고했습니다. 소아 폐렴 사망자의 거의 80%가 개발도상국의 2세 미만 어린이에게서 발생합니다. 따라서 폐렴의 유병률 증가는 폐렴 치료제 시장의 확대를 촉진하고 있습니다.

폐렴 치료제 시장의 주요 기업은 항생제 내성을 다루고 환자의 예후를 개선하기 위해 혁신적인 약물 제제와 치료 방법에 주력하고 있습니다. Limited와 공동으로 세페핌-엔메타조박탐을 출시했습니다.이 항생제의 조합은 요로 감염(UTI)과 폐렴과 같은 복잡한 감염, 특히 다른 약물에 내성이있는 감염을 치료하기 위해 설계되었습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계의 폐렴 치료제 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
• 최종 이용 산업의 분석
• 세계 폐렴 치료제 시장 : 성장률 분석
• 세계의 폐렴 치료제 시장 실적 : 규모와 성장(2019-2024년)
• 세계의 폐렴 치료제 시장 예측 : 규모와 성장(2024-2029년, 2034년)
• 세계의 폐렴 치료제 총 시장 규모(TAM)

제6장 시장 세분화

• 세계의 폐렴 치료제 시장 : 제품별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 약물
• 백신
• 산소 치료
• 세계의 폐렴 치료제 시장 : 감염별 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원 획득성 폐렴(HAP)
• 지역사회 획득 폐렴(CAP)
• 인공호흡기 관련 폐렴(VAP)
• 세계의 폐렴 치료제 시장 : 투여 경로별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 경구
• 비경구
• 기타 투여 경로
• 세계의 폐렴 치료제 시장 : 최종 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 병원
• 홈케어
• 전문 클리닉
• 기타 최종 사용자
• 세계의 폐렴 치료제 시장 : 약물 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 항생제
• 항바이러스제
• 항진균제
• 코르티코스테로이드
• 기타 약물
• 세계의 폐렴 치료제 시장 : 백신 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 폐렴구균 백신
• 인플루엔자균 b형(Hib) 백신
• 인플루엔자 백신
• 기타 백신
• 세계의 폐렴 치료제 시장 : 산소 치료 유형별 세분화, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 고유량 비강 캐뉼라(HFNC)
• 비침습적 인공호흡(NIV)
• 기계적 인공호흡기
• 기타 산소 치료

제7장 지역별 및 국가별 분석

• 세계의 폐렴 치료제 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
• 세계의 폐렴 치료제 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

• 폐렴 치료제 시장 : 경쟁 구도
• 폐렴 치료제 시장 : 기업 프로파일
  • Pfizer Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • Roche AG 개요, 제품 및 서비스, 전략 및 재무 분석
  • Merck & Co. Inc. 개요, 제품 및 서비스, 전략 및 재무 분석
  • AbbVie Inc 개요, 제품 및 서비스, 전략 및 재무 분석
  • Bayer AG 개요, 제품 및 서비스, 전략 및 재무 분석

제31장 기타 주요 기업 및 혁신 기업

• Sanofi SA
• AstraZeneca PLC
• Abbott Laboratories
• Novartis AG
• GSK plc
• Eli Lilly and Company
• Astellas Pharma Inc.
• Eisai Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Cipla Inc.
• Hikma Pharmaceuticals PLC
• Shionogi & Co. Ltd
• Lupin Limited
• Swedish Orphan Biovitrum AB
• Nabriva Therapeutics plc

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

• 폐렴 치료제 시장(2029년) : 새로운 기회를 제공하는 국가
• 폐렴 치료제 시장(2029년) : 새로운 기회를 제공하는 부문
• 폐렴 치료제 시장(2029년) : 성장 전략
  • 시장 동향에 기초한 전략
  • 경쟁 전략

제36장 부록

HBR

영문 목차

영문목차

Pneumonia therapeutics encompass treatments and medications designed to manage and treat pneumonia, a lung infection caused by bacteria, viruses, or fungi. These therapeutics work by targeting the underlying pathogens, reducing inflammation, and improving respiratory function. Treatments include antibiotics for bacterial pneumonia, antiviral drugs for viral pneumonia, and antifungal agents for fungal infections.

The main products in pneumonia therapeutics include drugs, vaccines, and oxygen therapy. Pneumonia drugs address the root cause by using antibiotics, antivirals, antifungals, and supportive treatments such as oxygen therapy. The infections treated include hospital-acquired pneumonia (HAP), community-acquired pneumonia (CAP), and ventilator-associated pneumonia (VAP). Routes of administration include oral, parenteral, and other methods, with end users spanning hospitals, home care, specialty clinics, and other healthcare facilities.

The pneumonia therapeutics market research report is one of a series of new reports from The Business Research Company that provides pneumonia therapeutics market statistics, including the pneumonia therapeutics industry's global market size, regional shares, competitors with a pneumonia therapeutics market share, detailed pneumonia therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the pneumonia therapeutics industry. This pneumonia therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pneumonia therapeutics market size has grown rapidly in recent years. It will grow from $10.35 billion in 2024 to $11.49 billion in 2025 at a compound annual growth rate (CAGR) of 11.0%. The growth in the historic period can be attributed to the increasing prevalence of drug-resistant strains, rising awareness of pneumonia prevention, growth in elderly and immunocompromised populations, expanded vaccination programs, and improvements in healthcare infrastructure.

The pneumonia therapeutics market size is expected to see rapid growth in the next few years. It will grow to $17.26 billion in 2029 at a compound annual growth rate (CAGR) of 10.7%. The growth in the forecast period can be attributed to the increasing prevalence of antibiotic-resistant strains, the rising incidence of pneumonia in aging populations, the expansion of telemedicine for early diagnosis, growing healthcare expenditures in emerging markets, increased funding for infectious disease research, and heightened awareness campaigns. Key trends expected during this period include the development of monoclonal antibodies, the adoption of inhalable antibiotics, innovations in mRNA-based vaccines, AI-driven diagnostic tools, the use of host-targeted therapies, novel immunomodulators, and advancements in rapid point-of-care diagnostic platforms.

The increasing prevalence of pneumonia is expected to drive the growth of the pneumonia therapeutics market. Pneumonia is a lung infection that causes inflammation in the air sacs, leading to symptoms such as cough, fever, and difficulty breathing. The rising incidence of pneumonia is attributed to factors including aging populations, air pollution, smoking, weakened immune systems, antimicrobial resistance, and the spread of respiratory infections such as COVID-19 and influenza. Pneumonia therapeutics are designed to combat the infection's underlying cause whether bacterial, viral, or fungal through targeted medications while supporting recovery with oxygen therapy, anti-inflammatory drugs, and symptom management. For example, in January 2023, the National Center for Biotechnology Information reported that pneumonia affects approximately 120 million people worldwide each year, resulting in around 1.3 million deaths. Nearly 80% of pediatric pneumonia fatalities occur in children under two years old in developing nations. As a result, the growing prevalence of pneumonia is fueling the expansion of the pneumonia therapeutics market.

Leading companies in the pneumonia therapeutics market are focusing on innovative drug formulations and treatment methods to address antibiotic resistance and enhance patient outcomes. Antibiotic drugs play a crucial role in treating bacterial infections, including pneumonia. In June 2024, Orchid Pharma Limited, an India-based pharmaceutical company, collaborated with Cipla Limited, another India-based pharmaceutical firm, to introduce cefepime-enmetazobactam. This antibiotic combination is designed to treat complex infections, such as urinary tract infections (UTIs) and pneumonia, particularly those resistant to other medications. By combating bacterial resistance, it ensures more effective treatment while reducing the need for stronger antibiotics.

In August 2022, GSK plc, a UK-based pharmaceutical company, acquired Affinivax Inc. for an undisclosed amount. This acquisition allows Affinivax to continue its work under GSK's leadership, focusing on next-generation pneumococcal vaccines. Affinivax Inc. is a US-based biopharmaceutical company specializing in developing vaccines to prevent pneumonia and other diseases caused by Streptococcus pneumoniae. This strategic move strengthens GSK's pneumonia vaccine portfolio, reinforcing its position in the market.

Major players in the pneumonia therapeutics market are Pfizer Inc., Roche AG, Merck & Co. Inc., AbbVie Inc, Bayer AG, Sanofi S.A., AstraZeneca PLC, Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Astellas Pharma Inc., Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Inc., Hikma Pharmaceuticals PLC, Shionogi & Co. Ltd, Lupin Limited, Swedish Orphan Biovitrum AB, Nabriva Therapeutics plc, TaiGen Biotechnology Co. Ltd, Aridis Pharmaceuticals Inc., and Tergene Biotech Limited.

North America was the largest region in the pneumonia therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pneumonia therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the pneumonia therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pneumonia therapeutics market consists of revenues earned by entities by providing services such as chest X-rays, blood tests, sputum culture, oxygen supplementation, mechanical ventilation, and telemedicine consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The pneumonia therapeutics market also includes sales of pneumococcal vaccines, antibiotics, nebulizers, and inhalers. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values, that is, revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Pneumonia Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pneumonia therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pneumonia therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The pneumonia therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Drugs; Vaccine; Oxygen Therapy
• 2) By Infection: Hospital-Acquired Pneumonia (HAP); Community-Acquired Pneumonia (CAP); Ventilator-Associated Pneumonia (VAP)
• 3) By Route Of Administration: Oral; Parenteral; Other Routes Of Administration
• 4) By End Use: Hospitals; Homecare; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Drugs: Antibiotics; Antiviral Drugs; Antifungal Drugs; Corticosteroids; Other Drugs
• 2) By Vaccine: Pneumococcal Vaccines; Haemophilus Influenzae Type B (Hib) Vaccines; Influenza Vaccines; Other Vaccines
• 3) By Oxygen Therapy: High-Flow Nasal Cannula (HFNC); Non-Invasive Ventilation (NIV); Mechanical Ventilation; Other Oxygen Therapies
• Companies Mentioned:Pfizer Inc.; Roche AG; Merck & Co. Inc.; AbbVie Inc; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Pneumonia Therapeutics Market Characteristics

3. Pneumonia Therapeutics Market Trends And Strategies

4. Pneumonia Therapeutics Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Pneumonia Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Pneumonia Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Pneumonia Therapeutics Market Growth Rate Analysis
• 5.4. Global Pneumonia Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Pneumonia Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Pneumonia Therapeutics Total Addressable Market (TAM)

6. Pneumonia Therapeutics Market Segmentation

• 6.1. Global Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drugs
• Vaccine
• Oxygen Therapy
• 6.2. Global Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital-Acquired Pneumonia (HAP)
• Community-Acquired Pneumonia (CAP)
• Ventilator-Associated Pneumonia (VAP)
• 6.3. Global Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parenteral
• Other Route Of Administrations
• 6.4. Global Pneumonia Therapeutics Market, Segmentation By End Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Homecare
• Specialty Clinics
• Other End Users
• 6.5. Global Pneumonia Therapeutics Market, Sub-Segmentation Of Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antibiotics
• Antiviral Drugs
• Antifungal Drugs
• Corticosteroids
• Other Drugs
• 6.6. Global Pneumonia Therapeutics Market, Sub-Segmentation Of Vaccine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Pneumococcal Vaccines
• Haemophilus Influenzae Type B (Hib) Vaccines
• Influenza Vaccines
• Other Vaccines
• 6.7. Global Pneumonia Therapeutics Market, Sub-Segmentation Of Oxygen Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• High-Flow Nasal Cannula (HFNC)
• Non-Invasive Ventilation (NIV)
• Mechanical Ventilation
• Other Oxygen Therapies

7. Pneumonia Therapeutics Market Regional And Country Analysis

• 7.1. Global Pneumonia Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Pneumonia Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Pneumonia Therapeutics Market

• 8.1. Asia-Pacific Pneumonia Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Pneumonia Therapeutics Market

• 9.1. China Pneumonia Therapeutics Market Overview
• 9.2. China Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Pneumonia Therapeutics Market

• 10.1. India Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Pneumonia Therapeutics Market

• 11.1. Japan Pneumonia Therapeutics Market Overview
• 11.2. Japan Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Pneumonia Therapeutics Market

• 12.1. Australia Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Pneumonia Therapeutics Market

• 13.1. Indonesia Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Pneumonia Therapeutics Market

• 14.1. South Korea Pneumonia Therapeutics Market Overview
• 14.2. South Korea Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Pneumonia Therapeutics Market

• 15.1. Western Europe Pneumonia Therapeutics Market Overview
• 15.2. Western Europe Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Pneumonia Therapeutics Market

• 16.1. UK Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Pneumonia Therapeutics Market

• 17.1. Germany Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Pneumonia Therapeutics Market

• 18.1. France Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Pneumonia Therapeutics Market

• 19.1. Italy Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Pneumonia Therapeutics Market

• 20.1. Spain Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Pneumonia Therapeutics Market

• 21.1. Eastern Europe Pneumonia Therapeutics Market Overview
• 21.2. Eastern Europe Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Pneumonia Therapeutics Market

• 22.1. Russia Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Pneumonia Therapeutics Market

• 23.1. North America Pneumonia Therapeutics Market Overview
• 23.2. North America Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Pneumonia Therapeutics Market

• 24.1. USA Pneumonia Therapeutics Market Overview
• 24.2. USA Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Pneumonia Therapeutics Market

• 25.1. Canada Pneumonia Therapeutics Market Overview
• 25.2. Canada Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Pneumonia Therapeutics Market

• 26.1. South America Pneumonia Therapeutics Market Overview
• 26.2. South America Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Pneumonia Therapeutics Market

• 27.1. Brazil Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Pneumonia Therapeutics Market

• 28.1. Middle East Pneumonia Therapeutics Market Overview
• 28.2. Middle East Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Pneumonia Therapeutics Market

• 29.1. Africa Pneumonia Therapeutics Market Overview
• 29.2. Africa Pneumonia Therapeutics Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Pneumonia Therapeutics Market, Segmentation By Infection, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Pneumonia Therapeutics Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Pneumonia Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Pneumonia Therapeutics Market Competitive Landscape
• 30.2. Pneumonia Therapeutics Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Roche AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AbbVie Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Pneumonia Therapeutics Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. AstraZeneca PLC
• 31.3. Abbott Laboratories
• 31.4. Novartis AG
• 31.5. GSK plc
• 31.6. Eli Lilly and Company
• 31.7. Astellas Pharma Inc.
• 31.8. Eisai Co. Ltd.
• 31.9. Sun Pharmaceutical Industries Ltd.
• 31.10. Cipla Inc.
• 31.11. Hikma Pharmaceuticals PLC
• 31.12. Shionogi & Co. Ltd
• 31.13. Lupin Limited
• 31.14. Swedish Orphan Biovitrum AB
• 31.15. Nabriva Therapeutics plc

32. Global Pneumonia Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Pneumonia Therapeutics Market

34. Recent Developments In The Pneumonia Therapeutics Market

35. Pneumonia Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Pneumonia Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Pneumonia Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Pneumonia Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료